

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 200043843 B2
(10) Patent No. 759197

(54) Title
**Transfecting compounds which are sensitive to reducing conditions,
pharmaceutical compositions containing them and their applications**

(51)⁷ International Patent Classification(s)
C07K 005/062 A61P 043/00
A61K 038/05 C07C 019/00

(21) Application No: **200043843**

(22) Application Date: **2000.07.04**

(30) Priority Data

(31) Number	(32) Date	(33) Country
98/01065	1998.01.30	FR
60/077026	1998.03.06	US

(43) Publication Date : **2001.04.05**

(43) Publication Journal Date : **2001.04.05**

(44) Accepted Journal Date : **2003.04.10**


(71) Applicant(s)
Aventis Pharma S.A.

(72) Inventor(s)
Gerardo Byk; Catherine Dubertret; Bruno Pitard; Daniel Scherman

(74) Agent/Attorney
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000

ABSTRACT

The invention concerns a novel agent for transferring nucleic acids into cells. Said agent is particularly characterised in that it comprises one or several disulphide bonds sensitive to reducing conditions. The invention also concerns compositions comprising such an agent for transferring in vitro, in vivo, or ex vivo nucleic acids of interest into different cell types.



AUSTRALIA
PATENTS ACT 1990
COMPLETE SPECIFICATION

NAME OF APPLICANT(S):

Aventis Pharma S.A.

ADDRESS FOR SERVICE:

DAVIES COLLISON CAVE
Patent Attorneys
1 Little Collins Street, Melbourne, 3000.

INVENTION TITLE:

Transfecting compounds which are sensitive to reducing conditions,
pharmaceutical compositions containing them and their applications

The following statement is a full description of this invention, including the best method of performing it known to me/us:-

The present invention relates to a new agent
5 for transferring nucleic acids into cells. This
transfer agent is more particularly characterized in
that it contains one or more disulphide bridges which
are sensitive to reducing conditions. This new agent
can be used to transfer nucleic acids of interest into
10 different cell types either *in vitro*, *in vivo* or *ex*
vivo.

With the development of biotechnology, the
possibility of effectively transferring nucleic acids
into cells has become a necessity. It involves the
15 transfer of nucleic acids into cells *in vitro*, for
example, for the production of recombinant proteins, or
in the laboratory for studying the regulation of the
expression of genes, the cloning of genes, or any other
manipulation involving DNA. It may also involve the
20 transfer of nucleic acids into cells *in vivo*, for
example for the creation of transgenic animals, the
production of vaccines, labelling studies or also
therapeutic approaches. It may also be the transfer of
nucleic acids into cells *ex vivo*, in approaches
25 including bone marrow transplants, immunotherapy or
other methods involving the transfer of genes into
cells collected from an organism for the purpose of
their subsequent readministration.

The various synthetic vectors developed so far in order to improve the transfer of nucleic acids into cells possess a considerable structural diversity which reflects the observation of the fact that their efficiency is different depending on the desired application and the intended cell types. This efficiency is largely dependent on their structure.

Among the synthetic vectors developed hitherto, cationic lipids have an important place. These vectors consist of a cationic polar part which interacts with the nucleic acids, and a hydrophobic lipid part which enables the complex formed to be protected from the external medium. The following may be mentioned by way of example: the monocationic lipids (DOTMA: Lipofectin[®]); lipopolyamines, in particular dioctadecylamidoglycyl spermine (DOGS) or 5-carboxy-spermylamide of palmitoylphosphatidylethanolamine (DPPES), whose preparation has been described, for example, in Patent Application EP 394 111; or else the cationic lipids cited in Applications WO 96/17823 and WO 97/18185 (incorporated into the present by way of reference).


Many studies have clearly indicated that cationic lipids possess properties which make it possible to promote transfection. However, it now appears necessary to develop cationic lipids having novel structures which make it possible to provide additional beneficial properties. Thus, there is a need

for cationic lipids which would be more particularly
suitable for crossing membrane barriers. Indeed,
numerous obstacles prevent a real transfection
efficiency, among which the difficulty for the nucleic
5 acid to cross biological membranes and to penetrate
into the cellular compartments ("*Cellular and Molecular
Barriers to Gene Transfer by a Cationic Lipid*",
Zabner, J. et al., J. Biol. Chem., 1995, No. 32, 18997-
19007). It is this technical difficulty which the
10 present invention proposes to solve.

Thus, the present invention relates to novel
nucleic acid transfer agents which comprise at least
one cationic hydrophilic region capable of
noncovalently combining with nucleic acids and at least
15 one lipophilic region, these regions being connected to
each other through a so-called "spacer" arm, and
comprising, in addition, at least one disulphide bridge
positioned such that its reduction causes partial
degradation of the lipophilic region, or alternatively
20 positioned such that its reduction causes separation of
the said transfer agent when it is symmetrical.

These transfer agents are capable of
efficiently complexing nucleic acids by virtue of their
cationic hydrophilic parts, this interaction strongly
25 compacting the said nucleic acid, and the lipophilic
region makes this ionic interaction insensitive to the
external medium by covering the particle formed with a
lipid film.

However, in addition to these properties which are desired for vectorization, the transfer agents according to the invention possess an extremely advantageous detergent property, by generating, at the level of the reducing cellular medium, because of the presence of the disulphide bridge(s), molecules of the polyaminated alkyl chain type which are membrane destabilizers. Indeed, the disulphide bridges are capable of constituting stable covalent bonds in oxidizing medium, and of breaking in reducing medium, according to the following scheme:



This type of structure is present, for example, in certain proteins possessing cysteine amino acids, and contributes to their three-dimensional structure and therefore to their biological activity. Disulphide bridges have, moreover, already been introduced into certain chimeric proteins, and in particular into immunotoxins, in order to connect the targeting domain to the active domain.

"Reducing medium" is understood to mean, for the purposes of the invention, a natural reducing medium, for example the intracellular medium, in particular the cytoplasm and in particular the endosomes. An artificial reducing medium representative of natural conditions is for example a medium comprising 0.1% to 20% of dithiotreitol (DTT).

By contrast, "oxidizing medium" is understood to mean any medium which is in contact with atmospheric oxygen and which contains no reducing agent, in particular the extracellular medium. A representative oxidizing medium
5 for example consists of a 150 mM isotonic solution of sodium chloride, or of a solution containing 5% glucose.

The Applicant has thus demonstrated, quite unexpectedly, that one of the disulphide bridges could
10 be introduced into a synthetic vector for the transfer of nucleic acids, in particular of the cationic lipid type, and that this did not affect its capacity to complex the nucleic acids in a non-reducing medium. It also shows that the nucleic acid transfer properties of
15 these agents are preserved, or even improved. Moreover, the complexes formed are degraded in reducing medium, and therefore in particular in the cell, which makes it possible to generate detergent molecules, thus making a larger quantity of nucleic acid accessible to the
20 cellular transcription machinery.

"Detergent" is understood to mean, for the purposes of the invention, any amphiphilic molecule having the property of being inserted into biological membranes and destabilizing them. This results from the
25 capacity of detergents amphiphilic molecules to rupture the membranes by becoming inserted into the phospholipid double layers and by solubilizing the

lipids and the proteins (*La Cellule*, Ed. Vigot and Décarie, 1988, pp. 581-583).

Another advantage of the transfer agents according to the invention also consists in their
5 reduced intrinsic toxicity. Indeed, the transfer agent being degraded in the cell at the level of the disulphide bridges which are sensitive to reducing conditions, it does not exert the toxic effect observed for conventional transfer vectors. Furthermore, the
10 improvement of the passage across the membranes allows the use of smaller doses of nucleic acid/transfer agent complex, with the beneficial consequences resulting therefrom on toxicity.

Finally, the Applicant has also demonstrated
15 that the transfer properties are significantly improved when the lipophilicity of the transfer agents is sufficient and when they are used in adequate quantity. More particularly, it has been shown that one of the major advantages of increasing the lipophilicity of
20 these agents, or of introducing a chain derived from a steroid, is the induction of improved resistance to serum.

The transfer agents according to the invention can have two types of structure, without this
25 having an influence on their technical effect. In the first case, this structure can be represented in the following manner:

cationic hydrophilic region — spacer — lipophilic region

In such a structure, the disulphide bridge(s) are positioned in the lipophilic region so as to generate a detergent amphiphilic molecule when they are reduced.


The second type of structure can be represented as follows:

10 cationic hydrophilic region — spacer — lipophilic region
 cationic hydrophilic region — spacer — lipophilic region

In this case, the disulphide bridge(s) are positioned so that their reduction causes separation of the two symmetrical parts of the transfer agent, that is to say between the two spacer parts.


For the purposes of the invention, "cationic hydrophilic part" is understood to mean any hydrophilic molecule whose overall charge is positive at physiological pH, that is to say between pH 5 and 8, and possessing, in addition, properties of bonding with nucleic acids. This bond is in particular of the noncovalent bond type, such as for example ionic interactions. Preferably, the cationic hydrophilic region present in the transfer agents according to the invention is a polyamine or a polyaminoguanidine.

According to an advantageous variant, the cationic hydrophilic region corresponds to the following general formula:



in which m is an integer greater than or equal to 2 and
 1 is an integer greater than or equal to 1, it being
 possible for m to vary between the different groups of
 carbon between two amines. Preferably, m is between 2
 5 and 6 inclusive, and l is between 1 and 5 inclusive.
 Still more preferably, the polyamine region is
 represented by spermine.

Another preferred polyamine region
 corresponds to the following general formula described
 10 in Application WO 97/18185:



in which R_1 , R_2 and R_3 represent, independently of each
 15 other, a hydrogen atom or a group $-(CH_2)_q-NRR'$ with q
 being capable of varying between 1, 2, 3, 4, 5 and 6
 independently between the different groups R_1 , R_2 and
 R_3 , and R and R' represent, independently of each other,
 a hydrogen atom or a group $-(CH_2)_q-NH_2$ with q defined as
 20 above, and m and n represent, independently of each
 other, an integer capable of varying between 0 and 6
 with, when n is greater than 1, m being capable of
 taking different values and R_3 different meanings in the
 above general formula.

25 The lipophilic region present in the transfer
 agents according to the invention consists of at least

one fatty aliphatic chain and of one or more other aliphatic chains, of one or more steroid derivatives, of a natural or synthetic lipid, or optionally a combination of these, preferably capable of forming
 5 lamellar or hexagonal phases. These structures are characterized by the distances between the lamellae or the tubes which depend on the length of the fatty aliphatic chain or of the polar part of the lipid.

The term "fatty aliphatic chain" designates,
 10 for the purposes of the invention, a linear or branched alkyl chain comprising 10 to 22 carbon atoms, optionally saturated and/or fluorinated. Preferably, it comprises 12 to 22 carbon atoms. There may be mentioned more particularly the C_{12} , C_{13} , C_{14} , C_{16} , C_{18} and C_{19}
 15 aliphatic groups and the like, and in particular the $(CH_2)_{11}CH_3$, $(CH_2)_{12}CH_3$, $(CH_2)_{13}CH_3$, and $(CH_2)_{17}CH_3$ groups.

When the lipophilic region comprises a derivative of a steroid, the latter is preferably chosen from cholesterol, cholic acid or
 20 cholesterylamine.

In a preferred embodiment, the lipophilic region is composed of at least two fatty aliphatic chains. Still more preferably, it is composed of two or three fatty aliphatic chains.

25 According to another advantageous variant of the invention, the lipophilic part consists of a fatty aliphatic chain and a steroid derivative.

When the transfer agent according to the invention has a symmetrical structure, each symmetrical part of the molecule contains at least one fatty aliphatic chain.

5 The cationic hydrophilic region and the lipophilic region may be connected to each other through a so-called "spacer" arm. The spacer can be described, with no limitation being implied, as any acid or amine group comprising hydrolyzable functions,
10 which is known to persons skilled in the art.

Preferably, the so-called spacer region comprises an aliphatic or aromatic chain. Preferably, the spacer region may be, for example, chosen from amide, carbamate, ester or ether groups, or aromatic rings.

15 The transfer agents according to the invention comprise one or more disulphide bridges. The number of these bridges is determined by persons skilled in the art according to the structure of the transfer agent and the desired properties.

20 Advantageously, the transfer agent comprises one or two disulphide bridges, and preferably one disulphide bridge. In the transfer agent, the disulphide bridge(s) may be positioned at different sites. The position depends on the number of bridges and the structure of
25 the agent.

According to a first embodiment, the disulphide bridge is positioned such that its reduction causes partial degradation of the lipophilic region,

thus generating a detergent amphiphilic molecule at the level of the cell. This partial degradation may correspond in particular to the loss of an aliphatic chain when the lipophilic region comprises several thereof, or alternatively the loss of the chain derived from a steroid when the lipophilic region contains one thereof. "Loss of an aliphatic fatty chain" is understood to mean either the complete loss thereof, or a partial loss, the remaining part then being too short to constitute a fatty chain (length of less than 10 carbon atoms). Such a rupture destroys the integrity of the complex which then gradually disintegrates to give dissociated components of which at least one is a detergent amphiphilic molecule. The degradation of the complex can be easily checked by microscopy or by electrophoresis.

According to another variant, the disulphide bridge is positioned between the two spacer arms of a transfer agent of symmetrical structure, such that its reduction causes the separation of the said transfer agent.

According to another variant, the disulphide bridge is positioned between the two spacer arms of a transfer agent of symmetrical structure, such that its reduction causes the separation of the said transfer agent.

Preferred transfer agents according to the invention comprise:

- as cationic hydrophilic region, a polyamine or polyaminoguanidine,

- as lipophilic region, at least two fatty aliphatic chains, or at least one chain derived from a steroid and one fatty aliphatic chain, and,

- a disulphide bridge whose reduction leads to the loss of a fatty aliphatic chain, or of a chain derived from a steroid when the transfer agent contains one.

10 In a particularly advantageous manner, the transfer agents of the invention comprise a polyamine region, three aliphatic chains of which at least two are fatty chains, and a disulphide bridge leading, in a reducing medium, to the loss of an aliphatic chain.

15 Other particularly advantageous transfer agents comprise a polyamine region, a fatty aliphatic chain and a chain derived from a steroid, and a disulphide bridge leading, in a reducing medium, to the loss of the chain derived from a steroid.

20 Other particularly advantageous transfer agents consist of two symmetric lipopolyamines, and of a disulphide bridge leading, in a reducing medium, to their separation.



Such agents are illustrated in the examples.

25 The following compounds may be mentioned with no limitation being implied:

CCCCSSC(=O)N(CCCCNC(=O)NCCCCN)C(=O)NCCCCNCCCCNCCCCNCCCCCCCCCCCCCCCCCNC(=O)CCSCCNC(=O)NCCCCNC(=O)NCCCCNC(=O)NNCCCCN(CCCCNC(=O)C(SS)CCCCCCCCCCCCCCCCCC)C(=O)NCCCCCCCCCCCCCCCCNCCCCNC(CCCN)C(=O)N[C@@H](CSSCCCCCCCCCCCCCCCCCCCCN)C(=O)NCCCCN

The chemical structure shows a steroid nucleus (estrane derivative) with a disulfide bridge (-S-S-) connecting it to a long aliphatic chain. The chain includes a carbonyl group (C=O) and a terminal primary amine group (H₂N). The steroid nucleus has several methyl groups and a side chain at the C-17 position.

(V)



Another subject of the invention relates to a composition comprising a transfer agent as defined above, and at least one nucleic acid. Preferably, the transfer agent and the nucleic acid are present in quantities such that the ratio of the positive charges of the agent to the negative charges of the nucleic acid is between 0.1 and 50. This ratio can be easily adjusted by persons skilled in the art depending on the agent used, the nucleic acid and the type of cells to be transfected. Advantageously, this ratio is between 3 and 12 nanomoles of agent according to the invention per μg of nucleic acid, and preferably between 3 and 9 nanomoles of transfecting agent per μg of nucleic acid.

For the purposes of the invention, "nucleic acid" is understood to mean both a deoxyribonucleic acid and a ribonucleic acid. They may be natural or artificial sequences, and in particular genomic DNA (gDNA), complementary DNA (cDNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), hybrid sequences or synthetic or semisynthetic sequences, oligonucleotides which are modified or otherwise. These

nucleic acids may be of human, animal, plant, bacterial or viral origin and the like. They may be obtained by any technique known to persons skilled in the art, and in particular by the screening of libraries, by

5 chemical synthesis or by mixed methods including the chemical or enzymatic modification of sequences obtained by the screening of libraries. They may be chemically modified, that is to say that they may be pseudonucleic acids (PNA), oligonucleotides modified by
10 various chemical bonds (for example phosphorothioate or methyl phosphonate), or alternatively oligonucleotides which are functionalized, that is to say which are coupled with one or more molecules having distinct characteristic properties.

15 As regards more particularly deoxyribonucleic acids, they may be single- or double-stranded, as well as short oligonucleotides or longer sequences. In particular, the nucleic acids advantageously consist of plasmids, vectors, episomes, expression cassettes and
20 the like. These deoxyribonucleic acids may carry genes of therapeutic interest, sequences for regulating transcription or replication, anti-sense sequences which are modified or otherwise, regions for binding to other cellular components, and the like.

25 Preferably, the nucleic acid comprises an expression cassette consisting of one or more genes of therapeutic interest under the control of one or more

promoters and of a transcriptional terminator which are active in the target cells.

For the purposes of the invention, "gene of therapeutic interest" is understood to mean in particular any gene encoding a protein product having a therapeutic effect. The protein product thus encoded may be a protein, a peptide, and the like. This protein product may be homologous in relation to the target cell (that is to say a product which is normally expressed in the target cell when the latter has no pathological condition). In this case, the expression of a protein makes it possible, for example, to palliate an insufficient expression in the cell or the expression of a protein which is inactive or weakly active because of a modification, or to overexpress the said protein. The therapeutic gene may also encode a mutant of a cellular protein, having increased stability, a modified activity and the like. The protein product may also be heterologous in relation to the target cell. In this case, an expressed protein may, for example, supplement or provide an activity which is deficient in the cell, allowing it to combat a pathological condition, or to stimulate an immune response.

Among the products of therapeutic interest for the purposes of the present invention, there may be mentioned more particularly enzymes, blood derivatives, hormones, lymphokines [interleukins, interferons, TNF,

and the like (FR 9,203,120)], growth factors, neurotransmitters or their precursors or synthesis enzymes, trophic factors [BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5, HARP/pleiotrophin, and the like],

5 dystrophin or a minidystrophin (FR 91/11947), the CFTR protein associated with cystic fibrosis, tumour suppressor genes [p53, Rb, Rap1A, DCC, k-rev, and the like (FR 93/04745)], genes encoding factors involved in coagulation [factors VII, VIII, IX], the genes involved

10 in DNA repair, suicide genes [thymidine kinase, cytosine deaminase], the genes for haemoglobin or other protein carriers, the genes corresponding to the proteins involved in the metabolism of lipids, of the apolipoprotein type chosen from apolipoproteins A-I,

15 A-II, A-IV, B, C-I, C-II, C-III, D, E, F, G, H, J and apo(a), metabolic enzymes such as for example lipoprotein lipase, hepatic lipase, lecithin cholesterol acyl transferase, 7-alpha-cholesterol hydroxylase, phosphatidic acid phosphatase, or lipid

20 transfer proteins such as the cholesterol ester transfer protein and the phospholipid transfer protein, an HDL-binding protein or a receptor chosen, for example, from the LDL receptors, the remnant chylomicron receptors and the scavenger receptors, and

25 the like.

The therapeutic nucleic acid may also be a gene or an anti-sense sequence, whose expression in the target cell makes it possible to control the expression

of genes or the transcription of cellular mRNAs. Such sequences can, for example, be transcribed in the target cell into RNAs which are complementary to cellular mRNAs and thus block their translation to protein, according to the technique described in Patent EP 140 308. The therapeutic genes also comprise the sequences encoding ribozymes, which are capable of selectively destroying target RNAs (EP 321 201).

As indicated above, the nucleic acid may also comprise one or more genes encoding an antigenic peptide, which is capable of generating an immune response in humans or in animals. In this specific embodiment, the invention therefore allows the production of vaccines or the carrying out of immunotherapeutic treatments applied to humans or to animals, in particular against microorganisms, viruses or cancers. They may be in particular antigenic peptides specific for the Epstein-Barr virus, the HIV virus, the hepatitis B virus (EP 185 573), the pseudo-rabies virus, the syncytia forming virus, other viruses, or specific for tumours (EP 259 212).

Preferably, the nucleic acid also comprises sequences allowing the expression of the therapeutic gene and/or the gene encoding the antigenic peptide in the desired cell or organ. They may be sequences which are naturally responsible for the expression of the gene considered when these sequences are capable of functioning in the infected cell. They may also be

sequences of different origin (responsible for the expression of other proteins, or even synthetic). In particular, they may be promoter sequences of eukaryotic or viral genes. For example, they may be
5 promoter sequences derived from the genome of the cell which it is desired to infect. Likewise, they may be promoter sequences derived from the genome of a virus. In this regard, there may be mentioned, for example, the promoters of the E1A, MLP, CMV and RSV genes, and
10 the like. In addition, these expression sequences may be modified by the addition of activating or regulatory sequences, and the like. The promoter may also be inducible or repressible.

Moreover, the nucleic acid may also comprise,
15 in particular upstream of the therapeutic gene, a signal sequence directing the therapeutic product synthesized in the secretory pathways of the target cell. This signal sequence may be the natural signal sequence of the therapeutic product, but it may also be
20 any other functional signal sequence, or an artificial signal sequence. The nucleic acid may also comprise a signal sequence directing the synthesized therapeutic product towards a particular compartment of the cell.

The compositions may, in addition, comprise
25 adjuvants capable of combining with the transfer agent/nucleic acid complex and of improving its transfecting power.

In this regard, the compositions according to the invention may comprise, as adjuvant, one or more neutral lipids. Such compositions are particularly advantageous, in particular when the ratio of the positive charges of the agent to the negative charges of the nucleic acid is low. The Applicant has indeed shown that the addition of a neutral lipid makes it possible to improve the formation of nucleolipid particles and, surprisingly, to promote cellular penetration by destabilizing the membrane.

More preferably, the neutral lipids used within the framework of the present invention are lipids containing two fatty chains.

In a particularly advantageous manner, natural or synthetic lipids which are zwitterionic or lacking ionic charge under physiological conditions are used. They may be chosen more particularly from dioleoylphosphatidylethanolamine (DOPE), oleoyl-palmitoylphosphatidylethanolamine (POPE), di-stearoyl, -palmitoyl, -cholesteryl, -myristoylphosphatidyl-ethanolamines as well as their derivatives which are N-methylated one to three times, phosphatidyl glycerols, glycosyldiacylglycerols, cerebrosides (such as in particular galactocerebrosides), sphingolipids (such as in particular sphingomyelins), or asialo-gangliosides (such as in particular asialoGM1 and GM2). These different lipids may be obtained either by synthesis or by extraction from organs (for example the

brain) or from eggs, by conventional techniques well known to persons skilled in the art. In particular, the extraction of the natural lipids may be carried out by means of organic solvents (see also Lehninger
5 Biochemistry).

More recently, the Applicant has demonstrated that it was also particularly advantageous to use, as adjuvant, a compound directly involved or otherwise in the condensation of the said nucleic acid, such as
10 those cited in Application WO 96/25508. The presence of such a compound in a lipopolyamine-based transfecting composition makes it possible to considerably reduce the quantity of this agent, with the beneficial consequences resulting therefrom from the toxicological
15 point of view, without any damaging effect on the transfecting activity of the said composition.

"Compound involved in the condensation of the nucleic acid" is intended to define a compound which compacts, directly or otherwise, the nucleic acid. More
20 precisely, this compound may either act directly at the level of the nucleic acid to be transfected, or may be involved at the level of an additional compound which is directly involved in the condensation of this nucleic acid. Preferably, it acts directly at the level
25 of the nucleic acid. In particular, the precompacting agent may be any polycation, for example polylysine. According to a preferred embodiment, this agent which is involved in the condensation of the nucleic acid is

derived, as a whole or in part, from a protamine, a histone, a nucleolin and/or one of their derivatives. Such an agent may also consist, as a whole or in part, of peptide units (KTPKKAKKP) and/or (ATPAKKAA), it
5 being possible for the number of units to vary between 2 and 10. In the structure of the compound according to the invention, these units may be repeated continuously or otherwise. They may thus be separated by linkages of a biochemical nature, for example one or more amino
10 acids, or of a chemical nature.

Preferably, the compositions of the invention comprise from 0.01 to 20 equivalents of adjuvant per equivalent of nucleic acids in weight/weight, and more preferably from 0.5 to 5.

15 The compositions according to the invention may also involve one or more targeting elements which make it possible to direct the nucleic complexes towards receptors or ligands at the surface of the cell. By way of example, the composition of the present
20 invention may comprise one or more antibodies directed against cell surface molecules, or one or more membrane receptor ligands such as insulin, transferrin, folic acid or any other growth factor, cytokines or vitamins. Advantageously, the composition may use lectins,
25 modified or otherwise, in order to target particular polysaccharides at the surface of the cell or on the neighbouring extracellular matrix. Proteins with an RGD unit, peptides containing a tandem of RGD units, which

is cyclic or otherwise, as well as polylysine peptides, can be used. More recently, natural or synthetic ligand peptides have also been described which are advantageous in particular for their selectivity
5 towards specific cells and which are capable of efficiently promoting internalization in these cells (Bary et al., Nature Medicine, 2, 1996, 299-305). These targeting agents are generally conjugated to the cationic transfection agent considered.

10 The invention also extends to any composition as defined above and comprising, in addition, one or more other agents known for transfecting the nucleic acid. In particular, there may be mentioned the products described in the Patent EP 394 111 and in
15 Patent Applications WO 96/17823, or WO 97/18185 (incorporated into the present by way of reference).

Another subject of the present invention also relates to the use of a transfer agent as defined above for transferring nucleic acids into cells.

20 The compositions comprising the transfer agent according to the invention can be formulated for administration by the topical, cutaneous, oral, rectal, vaginal, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal,
25 intratracheal or intraperitoneal route, and the like. Preferably, the pharmaceutical compositions of the invention contain a vehicle which is pharmaceutically acceptable for an injectable formulation, in particular

a direct injection into the desired organ, or for administration by the topical route (on the skin and/or the mucous membrane). They may be in particular isotonic sterile solutions, or dry, in particular freeze-dried, compositions which, upon addition, depending on the case, of sterilized water or of physiological saline, allow the constitution of injectable solutions. The nucleic acid doses used for the injection as well as the number of administrations may be adapted according to various parameters, and in particular according to the mode of administration used, the relevant pathological condition, the gene to be expressed, or the desired duration of treatment. As regards more particularly the mode of administration, it may be either a direct injection into the tissues or the circulatory system, or a treatment of cells in culture followed by their reimplantation by injection or transplantation.

The invention relates, in addition, to a method of transferring nucleic acids into cells comprising the following steps:

- (1) bringing the nucleic acid into contact with a transfer agent as defined above, to form a nucleic acid/transfer agent complex,
- (2) bringing the cells into contact with the complex formed in (1).

In the case of a composition comprising one or more other transfection agents and/or one or more

adjuvants, step (1) is preceded by a step of bringing the different transfection agents into contact and/or by a step of bringing the transfection agent into contact with the adjuvant(s).

5 The agent according to the invention/nucleic acid complexes are formed by mixing, volume for volume, two solutions, one containing the transfection agent according to the invention in the form of micelles or of a hexagonal lamellar phase, the other the nucleic
10 acid to be transfected. The complexes are formed within a few seconds. They may be negatively or positively charged or they may be neutral, depending on the quantity of lipid added to the nucleic acid (Pitard B. et al., *Proc. Natl. Acad. Sci. USA*, Vol. 94, pp. 14412-
15 14417, December 1997). The sizes of these complexes vary between 50 and 300 nm in diameter (measured by a quasielastic diffusion of light and by transmission electron microscopy). Moreover, the morphology of the complexes varies with the charge ratio R (ratio of the
20 positive charges provided by the cationic lipid to the negative charges provided by the nucleic acid). For example, the negatively charged complexes are surrounded by molecules of nucleic acid. Moreover, the positively charged complexes have cationic lipids at
25 their surface. As for the neutral complexes, they are colloidally unstable. The Applicant has thus shown that it was possible to stabilize them by adding a non-ionic surfactant in a sufficient quantity. Preferred

surfactants are in particular poloxamers, polyoxyethylene alcohols, polyoxyethylene nonyl phenyl ether or PEGs (polyethylene glycols) with a dendritic benzyl polyether head.

5 The cells are brought into contact with the complex by incubating the cells with the said complex (for uses *in vitro* or *ex vivo*), or by injecting the complex into an organism (for uses *in vivo*). The incubation is carried out preferably in the presence,
10 for example, of 0.01 to 1000 μg of nucleic acid per 10^6 cells. For *in vivo* administration, doses of nucleic acids ranging from 0.01 to 10 mg may be used.

 The transfer agents according to the invention are particularly advantageous for their use
15 in transferring nucleic acids into primary cells or into established lines. These may be fibroblast cells, muscle cells, nerve cells (neurons, astrocytes, glial cells), hepatic cells, haematopoietic cells (lymphocytes, CD34, dendritic cells, and the like),
20 epithelial cells and the like in differentiated or pluripotent form (precursors).

 The present invention thus provides a particularly advantageous method for the treatment of diseases comprising the *in vivo*, *ex vivo* or *in vitro*
25 administration of a nucleic acid capable of correcting the said disease, combined with a compound according to the invention. More particularly, this method is applicable to diseases resulting from a deficiency in

or a lack of protein or nucleic product. The administered nucleic acid encodes the said protein product or contains the said nucleic product.

In addition to the preceding arrangements, the present invention also comprises other characteristics and advantages which will emerge from the examples and figures which follow, and which should be considered as illustrating the invention without limiting the scope thereof. In particular, the Applicant proposes, with no limitation being implied, various operating protocols as well as reaction intermediates which can be used to prepare the transfer agents according to the invention. Of course, it is within the capability of persons skilled in the art to draw inspiration from these protocols or intermediate products in order to develop similar methods so as to lead to these same compounds.

Figures

Figure 1: Curve representing the profile for solubilization of liposomes EPC/EPA (10:1) by Triton X-100 by measurement of the turbidity of the solution with the aid of a spectrophotometer. The quantity of Triton X-100 added in mM is represented on the x-axis. The absorbance of the solution containing the liposomes is measured on the y-axis.

Figure 2: Curve representing the profile for solubilization of liposomes EPC/EPA (10:1) by compound (VII) by measurement of the turbidity of the

solution with the aid of a spectrophotometer. The quantity of compound (VII) added in mM is represented on the x-axis. The absorbance of the solution containing the liposomes is measured on the y-axis.

- 5 Figure 3: Activity of transfection of the compound (VI) into HepG2 cells in the absence of serum, compared with the cationic lipid of formula $\text{H}_2\text{N}(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COGly}[(\text{CH}_2)_{17}\text{CH}_3]_2$ used as reference transfer agent (called REF in the remainder of the application).

Figure 4: Activity of transfection of the compound (I) and of the compound (IV) into HepG2 and HeLa cells, in the presence and in the absence of serum, compared with the reference cationic lipid REF.

- 15 Figure 5: Histogram representing the activity of *in vitro* transfer into HeLa cells of the compound (I) without co-lipid or alternatively in the presence of a co-lipid DOPE or cholesterol. The y-axis represents the expression of luciferase in pg per well. The x-axis indicates the compound (I)/DNA ratio in nmol/ μg of DNA.

- 20 Figure 6: Histogram representing the activity of *in vitro* transfer into HeLa cells of the compound (IV) without co-lipid or alternatively in the presence of a co-lipid DOPE or cholesterol. The y-axis represents the expression of luciferase in pg per well. The x-axis indicates the compound (IV)/DNA ratio in nmol/ μg of DNA.

Figure 7: Activity of transfection of the compound (II) into HepG2 cells, in the presence and in the absence of serum, compared with the reference cationic lipid REF.

Figure 8: Histogram representing the activity of

5 in vitro transfer into HeLa cells of the compound (II) without co-lipid or alternatively in the presence of a co-lipid DOPE or cholesterol. The y-axis represents the expression of luciferase in pg per well. The x-axis indicates the compound (II)/DNA ratio in nmol/ μ g of
10 DNA.

Figure 9: Activity of transfection of the compound (V) into HepG2 and HeLa cells, in the presence and in the absence of serum, compared with the reference cationic lipid REF.

15

Examples

EXAMPLE 1: CHEMICAL SYNTHESSES OF THE TRANSFER AGENTS ACCORDING TO THE INVENTION

A. MATERIALS

20 - Triethylamine, N-ethyldiisopropylamine, dioctadecylamine, N_{α}, N_{α}' -diBococystine, and the BOP reagent are available commercially.

Likewise for amylamine, octadecylamine, penthanethiol, dodecanethiol, octadecanethiol and thiocholesterol.

25 - $\text{BocNH}(\text{CH}_2)_3 \text{NBoc}(\text{CH}_2)_4 \text{NBoc}(\text{CH}_2)_3 \text{NBocCH}_2\text{CO}_2\text{H}$ was synthesized in the laboratory according to the procedure described in Application WO 97/18185 and in

the article Byk G., Frederic M., and Scherman D.,
Tetrahedron Letters (1997) 38, 3219-3222.

B. METHODS

a) Spectroscopic analyses

5 The proton NMR spectra (Nuclear Magnetic
Resonance) were recorded on Bruker 250 and 400 MHz
spectrometers.

b) Chromatography techniques

The HPLC (High Performance Liquid
10 Chromatography) analyses are carried out on a HITACHI
apparatus equipped with an autosampler AS-2000A, a pump
L-6200A, a UV detector L 4000 at 220 nm, and an
integrator-calculator D 2500. The column used, marketed
by APPLIED BIOSYSTEMS, is made of stainless steel 3 cm
15 long and 4.6 mm in diameter. The mobile phases are
water and acetonitrile supplemented with trifluoro-
acetic acid, and the stationary phase is Aquapore butyl
7 micron. The flow rate varies between 1 and 4 ml/min.

The thin-layer chromatographies (TLC) are
20 performed on 20×20 aluminium plates coated with silica
gel.

c) Preparative HPLC purification

 - The equipment used is a set for liquid-
phase chromatography in gradient mode, allowing UV
25 detection. This preparative chain is composed of:

Pump A: GILSON model 305, equipped with a 50 SC head.

Pump B: GILSON model 303, equipped with a 50 SC head.

Injection pump: GILSON model 303, equipped with a 25 SC head.

Pressure module: GILSON model 806.

Mixer: GILSON model 811 C equipped with a 23 ml head.

- 5 UV Detector: GILSON model 119, equipped with a preparative cell, and set at 220 nm.

Fraction collector: GILSON model 202, equipped with No. 21 racks.

Integrator: SHIMADZU model C-R6A.


- 10 Column: Column C4 (10 mm) made of stainless steel 25 cm long and 2.2 cm in diameter, marketed by VYDAC model 214 TP 1022.

- The solution of product to be purified is loaded onto the column by the injection pump at the
15 flow rate of 15 ml/min. The mobile phases are water and acetonitrile.

C. CHEMICAL SYNTHESSES


a) Lipopolyamines with fatty chains which can be reduced by their disulphide bridge

- 20 These molecules have the general structure:




They were constructed in the following manner:


Step 1)



Step 2)



5 Step 3)



The following non-limiting examples illustrate these transfer agents:

compound (I): $R_1 = (CH_2)_4CH_3$; $R_2 = (CH_2)_{17}CH_3$;

10 $R_3 = (CH_2)_{17}CH_3$ [preparation 3.1]

compound (II): $R_1 = (\text{CH}_2)_{17}\text{CH}_3$; $R_2 = (\text{CH}_2)_{17}\text{CH}_3$; $R_3 = \text{H}$

[preparation 3.2]

compound (III): $R_1 = (\text{CH}_2)_{11}\text{CH}_3$; $R_2 = (\text{CH}_2)_{17}\text{CH}_3$; $R_3 = \text{H}$

[preparation 3.3]

5 compound (IV): $R_1 = (\text{CH}_2)_{11}\text{CH}_3$; $R_2 = (\text{CH}_2)_{17}\text{CH}_3$;

$R_3 = (\text{CH}_2)_{17}\text{CH}_3$ [preparation 3.4]

compound (V): $R_1 = \text{cholesteryl}$; $R_2 = (\text{CH}_2)_{17}\text{CH}_3$; $R_3 = \text{H}$

[preparation 3.5]

STEP 1

10 • PREPARATION 1.1 : $\text{NHBocCys}[\text{S-S-(CH}_2)_4\text{CH}_3]-\text{OH}$

$\text{N}_\alpha, \text{N}_\alpha'$ -diBoc-cystine (6.81 mmol) is dissolved in dimethylformamide (20 cm³). Triethylamine (58.1 mmol) is added to this solution followed by 1-pentanethiol (6.81 mmol). The mixture is stirred for 2 hours at room temperature. The triethylamine is evaporated and the concentrate is then added to a 0.5 M potassium sulphate (KHSO₄) solution (300 cm³). The product which precipitates is extracted with 3 times 100 cm³ of chloroform. The organic phases are combined and dried over anhydrous magnesium sulphate, and then the chloroform is evaporated off. The dry extract is solubilized with diethyl ether (100 cm³) and is then extracted with 3 times 50 cm³ of a saturated sodium carbonate (NaHCO₃) solution. The pooled aqueous phases are neutralized by adding, up to pH = 3, a 0.5 M KHSO₄ solution (350 cm³). The product which precipitates is extracted with 3 times 100 cm³ of chloroform. The pooled organic phases are washed with twice 50 cm³ of a

saturated sodium chloride (NaCl) solution and then dried over anhydrous magnesium sulphate. The chloroform is evaporated off in a rotary evaporator. The product obtained is eluted with a chloroform/methanol mixture
5 (9/1 v/v) on a silica column.

2.31 mmol of product are obtained, that is a yield of 34%.

TLC Rf = 0.63 (CHCl₃/MeOH, 9:1).

• PREPARATION 1.2 : NHBocCys[S-S-(CH₂)₁₇CH₃]-OH

10 N_α,N_α'-diBoc-cystine (6.81 mmol) is dissolved in dimethylformamide (20 cm³). Triethylamine (58.1 mmol) is added to this solution followed by 1-octadecanethiol (6.81 mmol). The mixture is stirred for 2 hours at 40°C. The triethylamine is evaporated off in a rotary
15 evaporator and the concentrate is then added to a 0.5 M KHSO₄ solution (300 cm³). The product which precipitates is extracted with 3 times 100 cm³ of chloroform. The organic phases are combined and dried over anhydrous magnesium sulphate and then the chloroform is
20 evaporated off. The dry extract is solubilized with diethyl ether (100 cm³) and is then washed with 3 times 50 cm³ of a saturated NaHCO₃ solution. The ethereal phase is acidified by beating with twice 100 cm³ of a 0.5 M KHSO₄ solution and then washed with twice 50 cm³
25 of a saturated NaCl solution. The ethereal phase is dried over anhydrous magnesium sulphate and is then evaporated to dryness in a rotary evaporator. The crude product obtained is crystallized from petroleum ether.

1.36 mmol of product are obtained ($Y = 20\%$).

TLC $R_f = 0.67$ ($\text{CHCl}_3/\text{MeOH}$, 9:1), HPLC $R_t = 17.80$ min.

• PREPARATION 1.3 : $\text{NHBocCys}[\text{S-S-Cholesterol}]\text{-OH}$

The synthesis is identical to preparation 1.2
5 but using thiocholesterol.

A yield of 58% is obtained.

TLC $R_f = 0.59$ ($\text{CHCl}_3/\text{MeOH}$, 9:1), HPLC $R_t = 19.16$ min.

• PREPARATION 1.4 : $\text{NHBocCys}[\text{S-S-(CH}_2\text{)}_{11}\text{CH}_3]\text{-OH}$

10 The synthesis is identical to preparation 1.2
but at room temperature and using 1-dodecanethiol.

A yield of 40% is obtained.

TLC $R_f = 0.69$ ($\text{CHCl}_3/\text{MeOH}$, 9:1), HPLC $R_t = 13.23$ min.

STEP 2

15 • PREPARATION 2.1 : $\text{NHBocCys}[\text{S-S-(CH}_2\text{)}_4\text{CH}_3]\text{-N}[(\text{CH}_2)_{17}\text{CH}_3]_2$

The product obtained in 1.1 (1.15 mmol) is
dissolved in dichloromethane (10 cm^3) and N-ethyldiiso-
propylamine (2.86 mmol), dioctadecylamine (1.15 mmol)
and BOP (1.27 mmol) are added.

20 The mixture is stirred for 2 hours and
monitored by TLC and HPLC.

The dichloromethane is evaporated off in a
rotary evaporator. The "crude product" is taken up in
chloroform (100 ml) and then washed successively with 3
25 times 50 cm^3 of 0.5 M KHSO_4 , and then with 3 times
 50 cm^3 of a saturated NaHCO_3 solution, and finally with
twice 50 cm^3 of a saturated NaCl solution. The organic
phase is dried over anhydrous magnesium sulphate and

then the chloroform is evaporated off in a rotary evaporator. A yield of 64% is obtained.

TLC Rf = 0.90 (CHCl₃/MeOH, 9:1), HPLC Rt = 25.96 min.

• PREPARATION 2.2: NHBocCys[S-S-(CH₂)₁₇CH₃]-NH(CH₂)₁₇CH₃

5 The synthesis is identical to preparation 2.1 but using the product obtained in preparation 1.4 as starting reagent.

A yield of 97% is obtained.

TLC Rf = 0.89 (CHCl₃/MeOH, 9:1), HPLC Rt = 24.84 min.

10 • PREPARATION 2.3 : NHBocCys[S-S-(CH₂)₁₁CH₃]-NH(CH₂)₁₇CH₃

 The synthesis is identical to preparation 2.1 but using the product of preparation 1.4 as starting reagent.

A yield of 86% is obtained.

15 TLC Rf = 0.90 (CHCl₃/MeOH, 9:1), HPLC Rt = 22.22 min.

• PREPARATION 2.4 : NHBocCys[S-S(CH₂)₁₁CH₃]-N[(CH₂)₁₇CH₃]₂

 The synthesis is identical to preparation 2.1 but using dioctadecylamine and the product of preparation 1.4 as starting reagents.

20 A yield of 85% is obtained.

TLC Rf = 0.90 (CHCl₃/MeOH, 9:1).

• PREPARATION 2.5 : NHBocCys[S-S-Cholesterol]-NH(CH₂)₁₇CH₃


 The synthesis is identical to preparation 2.1 but using octadecylamine and the product of preparation 1.3 as starting reagents.

A yield of 90% is obtained.

TLC Rf = 0.88 (CHCl₃/MeOH, 9:1), HPLC Rt = 26.98 min.

STEP 3

• PREPARATION 3.1 [compound (I)] :



5 Trifluoroacetic acid (10 cm³) is added to the product of preparation 2.1. The medium is stirred for 1.5 hours and the cleavage of BOC is monitored by HPLC. The trifluoroacetic acid is evaporated off and to drive off the traces, 3 times 5 ml of diethyl ether are
10 evaporated off.

 The dry extract is dissolved in 10 cm³ of dichloromethane and then N-ethyldiisopropylamine (3.34 mmol), BocNH(CH₂)₃ NBoc(CH₂)₄ NBoc(CH₂)₃ NBocCH₂CO₂H (0.644 mmol) and BOP (0.708 mmol) are added. The
15 mixture is stirred for 2 hours and the reaction is monitored by TLC and HPLC.

 The dichloromethane is evaporated off in a rotary evaporator. The crude product is taken up in chloroform (100 cm³) and then washed successively with 3
20 times 50 cm³ of 0.5 M KHSO₄, and then with 3 times 50 cm³ of a saturated NaHCO₃ solution, and finally with twice 50 cm³ of a saturated NaCl solution. The organic phase is dried over anhydrous magnesium sulphate and then the chloroform is evaporated off in a rotary
25 evaporator.

 Trifluoroacetic acid (10 cm³) is added to the dry extract. The medium is stirred for 1.5 hours and the cleavage of the BOCs is monitored by HPLC. The

trifluoroacetic acid is evaporated off and to drive off the traces, 3 times 5 cm³ of diethyl ether are evaporated off.

The crude product obtained is purified by preparative HPLC. The fractions of interest are combined and freeze-dried.

0.081 mmol of salified product is obtained, that is a yield of 11 %.

HPLC Rt = 17.79 min.

10 ¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, δ in ppm) : 0.90 (mt, 9H : CH₃ of the two octadecylamino groups and CH₃ of the pentyldisulphanyl) ; from 1.15 to 1.50 (mt, 64H : 15 CH₂ of one of the two octadecylamino groups - 15 CH₂ of the other octadecylamino) and 2 CH₂ of the pentyldisulphanyl) ; 1.47 (mt, 2H : 1 CH₂ of one of the two octadecylamino groups) ; from 1.55 to 1.75 (mt, 4H : 1 CH₂ of one of the two octadecylamino groups and 1 CH₂ of the pentyldisulphanyl) ; 1.65 (mf, 4H : the 2 central CH₂ groups of the butyl) ; from 1.85 to 2.05 (mt, 4H : the central CH₂ of the two propyls) ; from 2.70 to 2.85 (mt, 1H : 1H of the CH₂S of the cysteine) ; 2.78 (mt, 2H : SCH₂ of the pentyldisulphanyl) ; from 2.85 to 3.50 (mt : the 2 NCH₂ groups of the butyl - the 2 NCH₂ of the two propyls - the other H of the CH₂S of the cysteine and the NCH₂ of the two octadecylamino groups) ; 3.80 (broad s, 2H : NCH₂CON of the glycylamino) ; 5.07 (mt, 1H : CONCHCON of the cysteine) ; 9.05 (d, J' = 8 Hz, 1H : CONH of the

cysteine) ; 7.95 - 8.85 and from 8.90 to 9.15
(respectively 2 unres. comp. and broad unres. comp. :
the H atoms corresponding to the NH and NH₂ groups).

$\text{MH}^+ = 969$

5 • PREPARATION 3.2 [compound (II)] :

$\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys} - [\text{S}-\text{S}-(\text{CH}_2)_{17}\text{CH}_3] -$
 $\text{NH}(\text{CH}_2)_{17}\text{CH}_3$

The procedure is identical to that described
in preparation 3.1, but starting with the product
10 obtained in preparation 2.2..
A yield of 31% of salified product is obtained.
HPLC Rt = 15.63 min.
¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, δ in ppm) : 0.89
(t, J = 7.5 Hz, 6H : CH₃ of the octadecylamino and CH₃
15 of the octadecyldisulphanyl) ; from 1.15 to 1.45
(mt, 60H : 15 CH₂ of the octadecylamino) and 15 CH₂ of
the octadecyldisulphanyl) ; 1.42 (mt : 1 of the CH₂
groups of the octadecylamino) ; from 1.55 to 1.70 (mt,
2H : 1 of the CH₂ groups of the octadecyldisulphanyl) ;
20 1.66 (unres. comp., 4H : the 2 central CH₂ groups of the
butyl) ; from 1.85 to 2.05 (mt, 4H : the central CH₂ of
the two propyls) ; 2.76 (t, J = 7.5 Hz, 2H : SCH₂ of the
octadecyldisulphanyl) ; from 2.85 to 3.10 (mt, 14H :
the 2 NCH₂ of the butyl - the 2 NCH₂ of the two propyls
25 - 1H of the NCH₂ of the octadecylamino and 1H of the
CH₂S of the cysteine) ; 3.10 (dd, J = 13.5 and 6 Hz,
1H : the other H of the CH₂S of the cysteine) ; 3.18
(mt, 1H : the other H of the NCH₂ of the

octadecylamino) ; 3.82 (very limiting AB, 2H : NCH₂CON of the glycylamino) ; 4.60 (mt, 1H : CONCHCON of the cysteine) ; 8.27 (t, J = 5.5 Hz, 1H : CONH of the octadecylamino) ; 8.90 (d, J = 8.5 Hz, 1H : CONH of the cysteine) ; 7.95 - 8.82 and 9.07 (3 unres. comp. : the H atoms corresponding to the NH and NH₂ groups).

$$\underline{MH^+} = 899$$

• PREPARATION 3.3 [compound (III)] :

10 NH₂(CH₂)₃NH(CH₂)₄NH(CH₂)₃NHCH₂COCys-[S-S-(CH₂)₁₁CH₃]-NH(CH₂)₁₇CH₃

The procedure is identical to that described in preparation 3.1, but starting with the product obtained in preparation 2.3.

15 A yield of 26.5% of salified product is obtained.

HPLC Rt = 12.36 min.

¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, δ in ppm) : 0.90

(t, J = 7.5 Hz, 6H : CH₃ of the octadecylamino and CH₃ of the dodecylsulphanyl) ; from 1.15 to 1.50 (mt,

20 48H : 15 CH₂ of the octadecylamino and 9 CH₂ of the dodecylsulphanyl) ; 1.43 (mt : 1 CH₂ of the octadecylamino) ; from 1.55 to 1.70 (mt, 2H : 1 CH₂ of the dodecylsulphanyl) ; 1.65 (unres. comp., 4H : the 2 central CH₂ groups of the butyl) ; from 1.85 to 2.05
25 (mt, 4H : the central CH₂ of the two propyls) ; 2.76 (t, J = 7.5 Hz, 2H : SCH₂ of the dodecylsulphanyl) ; 2.80 to 3.05 (mt, 14H : the 2 NCH₂ of the butyl - the 2 NCH₂ of the two propyls - 1H of the NCH₂ of the

octadecylamino and 1H of the CH₂S of the cysteine) ;
 3.11 (dd, J = 13.5 and 6 Hz, 1H : the other H of the
 CH₂S of the cysteine) ; 3.17 (mt, 1H : the other H of
 the NCH₂ of the octadecylamino) ; 3.83 (limiting AB,
 5 2H : NCH₂CON of the glycylamino) ; 4.60 (mt, 1H :
 CONCHCON of the cysteine) ; 8.25 (t, J = 5.5 Hz , 1H :
 CONH of the octadecylamino) ; 8.99 (d, J = 8.5 Hz, 1H :
 CONH of the cysteine) ; 7.96 - 8.84 and 9.09 (3 unres.
 comp. : the H atoms corresponding to the NH and NH₂
 10 groups).

MH⁺ = 815

• PREPARATION 3.4 [compound (IV)] :

NH₂(CH₂)₃NH(CH₂)₄NH(CH₂)₃NHCH₂COCys-[S-S-(CH₂)₁₁CH₃]-
 N[(CH₂)₁₇CH₃]₂

15 The product obtained by preparation 2.4 is
 used in a synthesis identical to preparation 3.1.
 A yield of 39% of salified product is obtained.

HPLC Rt = 19.75 min.

¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, δ in ppm) : 0.87

20 (t, J = 7.5 Hz, 9H : CH₃ of the two octadecylamino
 groups and CH₃ of the dodecylsulphanyl) ; from 1.15 to
 1.50 (mt, 78H : 15 CH₂ of one of the two octadecylamino
 groups - 15 CH₂ of the other octadecylamino) and 9 CH₂
 of the dodecylsulphanyl) ; 1.47 (mt, 2H : 1 CH₂ of one
 25 of the two octadecylamino groups) ; from 1.50 to 1.70
 (mt, 4H : 1 CH₂ of one of the two octadecylamino groups
 and 1 CH₂ of the dodecylsulphanyl) ; 1.68 (unres.
 comp., 4H : the 2 central CH₂ groups of the butyl) ; from

1.85 to 2.10 (mt, 4H : the central CH₂ of the two propyls) ; 2.77 (t, J = 7.5 Hz, 2H : SCH₂ of the dodecyldisulphanyl) ; 2.80 (mt, 1H : 1H of the CH₂S of the cysteine) ; from 2.70 to 3.50 (mt : the 2 NCH₂ of the butyl - the 2 NCH₂ of the two propyls - the other H of the CH₂S of the cysteine and the NCH₂ of the two octadecylamino groups) ; 3.80 (broad s, 2H : NCH₂CON of the glycylamino) ; 5.05 (mt, 1H : CONCHCON of the cysteine) ; 9.07 (d, J = 8 Hz, 1H : CONH of the cysteine) ; from 7.75 to 8.20 and from 8.65 to 9.25 (2 broad unres. comp. : the H atoms corresponding to the NH and NH₂ groups).

$MH^+ = 1067$

• PREPARATION 3.5 [compound (V)] :

15 NH₂(CH₂)₃NH(CH₂)₄NH(CH₂)₃NHCH₂COCys-[S-S-Cholesterol]-
NH(CH₂)₁₇CH₃

The product obtained by preparation 2.5 is used in a synthesis identical to preparation 3.1 except for the final cleavage of the BOC groups for which the following mixture is used: 10 cm³ of TFA, 0.5 ml of water, 0.5 ml of thioanisole and 0.75 g of phenol. A yield of 5.6% of salified product is obtained.

HPLC Rt = 16.59 min.

¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, at a temperature of 383 K, δ in ppm) : 0.74 and 1.05 (2 s, 3H each : CH₃ in 18 and CH₃ in 19 of the cholesteryl) ; from 0.80 to 0.95 (mt : the H atoms corresponding to the CH₃ of the octadecylamino and to the CH₃ in 26 - CH₃ in 27 and CH₃

in 21 of the cholesteryl) ; 1.77 (mt : the 4H atoms corresponding to the 2 central CH₂ groups of the butyl) ; from 1.85 to 2.10 (mt : the 4H atoms corresponding to the central CH₂ of the two propyls) ;
 5 from 2.90 to 3.25 (mt : the 16H atoms corresponding to the 2 NCH₂ of the butyl - to the 2 NCH₂ of the two propyls - to the CH₂S of the cysteine and to the NCH₂ of the octadecylamino); 3.63 (limiting AB, 2H : NCH₂CON of the glycylamino) ; 4.61 (mt, 1H : CONCHCON of the
 10 cysteine) ; 5.39 (mt, 1H : CH in 6 of the cholesteryl) ; 7.69 (mt, 1H : CONH of the octadecylamino) ; 8.25 (unres. comp., 1H : CONH of the cysteine). For all the other protons of the cholesteryl and of the octadecylamino, the corresponding signals
 15 come out between 0.60 and 3.00 ppm.

$\text{MH}^+ = 1015$

b) Symmetric transfer agents which can be separated by a disulphide bridge

These molecules of general structure:

20

Polyamine — Spacer — Lipid

|

S

|

25


S

|


Polyamine — Spacer — Lipid

10 compound (VI): $R_1 = (CH_2)_{17}CH_3$; $R_2 = H$

5



a) TFA
b) BOP, DIEA/CH₂Cl₂
c) TFA



The following example, given with no (limitation being implied, illustrates one of these transfer agents:

STEP 1

- PREPARATION 1 : $[\text{NHBoc-CH}(\text{CO-NH}(\text{CH}_2)_{17}\text{CH}_3)\text{CH}_2\text{-S-}]_2$

$\text{N}_\alpha, \text{N}_\alpha'$ -diBoc-cystine (0.57 mmol) is dissolved in chloroform (15 cm³) and N-ethyldiisopropylamine (5.67 mmol), octadecylamine (0.10 mmol) and BOP (1.24 mmol) are added.


The mixture is stirred for 2 hours and monitored by TLC and HPLC.

The chloroform is evaporated off in a rotary evaporator. The "crude product" is taken up in ethyl acetate (100 cm³) and then washed successively with 3 times 50 cm³ of 0.5 M KHSO₄ and then with 3 times 50 cm³ of a saturated NaHCO₃ solution, and finally with twice 50 cm³ of a saturated NaCl solution. The organic phase is dried over anhydrous magnesium sulphate and then the ethyl acetate is evaporated off in a rotary evaporator. 0.346 mmol of product is obtained, that is a yield of 69%.

TLC R_f = 0.94 (CHCl₃/MeOH, 9:1).

20 STEP 2

- PREPARATION 2 [compound (VI)] :



Trifluoroacetic acid (5 cm³) is added to the product obtained by preparation 1. The mixture is stirred for 1.5 hours and the cleavage of the BOC is monitored by HPLC. The trifluoroacetic acid is evaporated off, and to drive off the traces, 3 times 5 cm³ of diethyl ether are evaporated off.

The dry extract is dissolved in dichloromethane (25 cm³), and then N-ethyl-diisopropylamine (3.44 mmol), BocNH(CH₂)₃ NBoc(CH₂)₄ NBoc(CH₂)₃ NBocCH₂CO₂H (0.697 mmol) and BOP (0.86 mmol) are added. The mixture is stirred for 2 hours and the reaction is monitored by TLC and HPLC.

The dichloromethane is evaporated off in a rotary evaporator. The "crude product" is taken up in ethyl acetate (100 cm³) and is then washed successively with 3 times 50 cm³ of 0.5 M KHSO₄ and then with 3 times 50 cm³ of a saturated NaHCO₃ solution, and finally with twice 50 cm³ of a saturated NaCl solution. The organic phase is dried over anhydrous magnesium sulphate and then the ethyl acetate is evaporated off in a rotary evaporator.

TLC R_f = 0.90 (CHCl₃/MeOH, 9:1), HPLC R_t = 26.10 min.

Trifluoroacetic acid (5 cm³) is added to the dry extract. The mixture is stirred for 1.5 hours and the cleavage of the BOC groups is monitored by HPLC. The trifluoroacetic acid is evaporated off, and to drive off the traces, 3 times 5 cm³ of diethyl ether are evaporated off.

The crude product obtained is purified by preparative HPLC. The fractions of interest are combined and freeze-dried.

0.099 mmol of salified product is obtained, that is a yield of 28.5 %, HPLC R_t = 10.55 min.

¹H NMR spectrum (400 MHz, (CD₃)₂SO-d₆, δ in ppm) : 0.91
 (t, J = 7.5 Hz, 6H : CH₃ of the two octadecylamino
 groups) ; from 1.10 to 1.40 (mt, 60H : 15 CH₂ of one of
 the two octadecylamino groups and 15 CH₂ of the other
 5 octadecylamino) ; 1.43 (mt, 4H : 1 CH₂ of the two
 octadecylamino groups) ; 1.64 (unres. comp., 8H : the 2
 central CH₂ groups of the two butyls) ; from 1.85 to
 2.10 (mt, 8H : the central CH₂ of the four propyls) ;
 from 2.80 to 3.15 (mt, 32H : the 2 NCH₂ of the two
 10 butyls - the 2 NCH₂ of the four propyls - the NCH₂ of
 the two octadecylamino groups and the CH₂S of the two
 cysteines) ; 3.84 (unres. comp., 4H : the NCH₂CON of the
 two glycylamino groups) ; 4.60 (mt, 2H : the CONCHCON
 of the two cysteines) ; 8.27 (unres. comp., 2H : the
 15 CONH of the two octadecylamino groups) ; 8.95 (unres.
 comp., 2H : the CONH of the two cysteines) ; 7.97 -
 8.87 and 9.15 (3 unres. comp. : the H atoms
 corresponding to the NH and NH₂ groups).
MH⁺ = 1227.

20

**EXAMPLE 2: EVALUATION OF THE DETERGENT ACTION OF THE
 TRANSFER AGENTS ACCORDING TO THE INVENTION**

The objective of this example is to show that
 the transfer agents according to the invention possess
 25 detergent properties, that is to say that they are
 capable of dissolving the membranes.

For that, an *in vitro* model is used which
 represents the biological membranes, namely liposomes

EPC/EPA (egg phosphatidylcholine/egg phosphatidic acid, 10:1). Just like biological membranes, the walls of these liposomes consist of phospholipid bilayers, and they therefore possess a comparable behaviour.

5 These liposomes are formed by dissolving the various constituents in chloroform, and then evaporating the said chloroform with the aid of a rotary evaporator. The lipid film obtained is redispersed in water, and then the liposomes are formed
10 by sonication and heating.

The evaluation of the detergent action of the product added to the liposomes is made by measuring the turbidity with the aid of a spectrophotometer.

By way of reference, a first experiment was
15 carried out with Triton X-100 which a well known commercially available detergent. Complete solubilization of the liposomes (100% solubilization) is then obtained as represented on the curve of Figure 1.

20 The second product tested is an amphiphilic molecule comprising a polyamine connected through a spacer to a fatty chain containing 18 carbon atoms (compound (VII)). It therefore corresponds to the molecule obtained by reducing the disulphide bridge of
25 the compound (II) of the present invention. The curve represented in Figure 2 shows the results obtained when this amphiphilic molecule is added to the liposomes: a partial solubilization is observed which corresponds to

a solubilization of about 30% compared with Triton X-100.

Finally, the same experiment was performed with the reference cationic lipid REF, namely the
5 analogue of the compound (II) but containing no disulphide bridge. No solubilization of the liposomal membranes was observed.

In conclusion, this example shows that the transfer agents according to the invention are capable
10 of generating, in reducing medium, amphiphilic molecules having a detergent action, that is to say capable of dissolving the membranes. This property is extremely advantageous because the transfer agents of the invention make it possible to vectorize nucleic
15 acids in a larger quantity and more easily up to the cellular compartments, which allows improvement of the transfection efficiency (as is shown in the transfection examples which follow).

EXAMPLE 3: USE OF THE PRODUCTS ACCORDING TO THE
20 **INVENTION FOR THE IN VITRO TRANSFECTION OF GENETIC**
MATERIAL

These tests illustrate the capacity of the transfer agents according to the invention to efficiently transfect cells *in vitro* in spite of the
25 insertion of disulphide bridge(s) into their structure.

A. GENETIC MATERIAL USED

The plasmid used is described in Patent WO 97/10343. This construct pCOR_pXL2774 comprises the

gene encoding luciferase under the human cytomegalovirus very early gene promoter [hCMV-IE].

The nucleic acid solutions are diluted to 20 µg/ml in physiological saline (0.15 M NaCl).

5 B. CYTOFECTANT SOLUTIONS (prepared immediately before use)

The products described in the invention are dissolved in water at a concentration varying from 40 to 160 µmol and mixed volume for volume with the DNA
10 solution. The final saline concentration is 75 mmol.

C. TRANSFECTION

The cells are cultured under appropriate conditions in 24-well microplates (2 cm²/well) and are transfected while they are in the exponential growth
15 phase and at 50-70% confluence.

The cells are washed with twice 0.5 cm³ of medium free of serum proteins and grown again either in serum-free medium (transfection in the absence of serum), or in complete medium (transfection in the
20 presence of serum). 0.05 cm³ of cytofectant mixture (0.5 µg DNA/well) are added to the cells (3 wells/condition DNA vector). When the cells are transfected in the absence of serum, the growth medium is supplemented 2 hours after transfection with the
25 appropriate quantity of serum.

The transfection efficiency is evaluated 48 hours post-transfection by measuring the expression of luciferase according to the recommendations given for

the use of the Promega kit (Luciferase Assay System). The toxicity of the cytofectant mixtures is estimated by a measurement of the protein concentrations in the cell lysates.

5 D. RESULTS

a) **Symmetric transfer agents which can be separated by reduction of a disulphide bridge : compound (VI)**
(Figure 3)

This product, described in the invention, was
10 used in comparison with the reference cationic lipid REF (described as being compound (6) in Patent Application WO 97/18185) as DNA vector, to transfect the cell line HepG2.

For this cell type, the toxicity of the
15 compound (VI) is of the same order of magnitude as that of the reference cationic liquid REF: when the transfection is carried out in the absence of serum proteins, the survival is 80% for the HepG2 cells, for cationic lipid doses of 160 μ M.

20 The maximum transfection efficiency is obtained for a cationic lipid/ μ g of DNA ratio of 4 to 8 nanomoles. The transgene expression obtained with the use of compound (VI) in comparison with that obtained with the reference cationic lipid REF is higher (4
25 times) for transfections of HepG2 cells.

b) Transfer agents whose lipid part is composed of two C₁₈ alkyl chains and of a third alkyl chain linked by a disulphide bridge : compounds (I) and (IV)

These two products, described in the present invention, exhibit no significant toxicity up to 160 µM of cationic lipid, both for HeLa cells and for HepG2 cells.

Compared with the expressions of the transgene obtained with the reference cationic lipid REF, the addition of a third C₅ lipid chain [compound (I)] makes it possible to obtain transfection results in the absence of serum proteins which are of the same order of magnitude. On the other hand, under the same transfection conditions, if the third lipid chain is a C₁₂ chain [compound (IV)], the expression of the transgene is increased by a factor of about 2-fold for the HeLa cells and of about 9-fold for the HepG2 cells (see Figure 4).

Furthermore, one of the major advantages of increasing the lipophilicity of the cationic lipids by adding a third alkyl chain is demonstrated in transfection experiments in the presence of serum proteins. In this case, there is indeed no significant inhibition due to the presence of the serum proteins, which makes them preferred candidates for *in vivo* transfections.

Figures 5 and 6 represent, in the form of histograms, the transfection efficiency of compounds (I) and (IV).

c) **Transfer agents whose lipid part is composed of two C₁₈ alkyl chains of which one is linked by a disulphide bridge : compound (II)**

This product, which is described in the invention, exhibits no significant toxicity at the doses used to the HepG2 cells (160 µM of cationic lipid).

For transfections in the absence of serum proteins, the level of the expression of the transgene is up to 3-fold higher compared with the reference cationic lipid REF (see Figure 7). Furthermore, the transfection is clearly improved (up to 40-fold) in the presence of serum proteins. Therefore, quite unexpectedly, there is no inhibitory effect due to the presence of serum.

Figure 8 represents, in the form of a histogram, the transfection efficiency of compounds (II).

d) **Transfer agents whose lipid part contains a chain derived from a steroid linked by a disulphide bridge : compound (V) (Figure 9)**

This compound, which is described in the invention, exhibits no significant toxicity at the doses used to the HeLa or HepG2 cells (160 µM of cationic lipid).

The binding of a cholesterol instead of an alkyl chain provides a very significant gain as regards the expression of the transgene and furthermore, in this case, no inhibition could be observed in the presence of serum proteins, which makes this product very attractive for use in transfection *in vivo*.

In conclusion, the results presented in the tables and histograms of Figures 3 to 9 show that:

- the introduction of disulphide bridge(s) into transfer agents of the cationic lipid type does not affect the capacity of these agents to transfect DNA *in vitro*, but leads, quite on the contrary, to an improvement in the transfection efficiency.
- the transfer agents according to the invention are not toxic at the doses used,
- and finally, the increase in the lipophilicity of the transfer agents according to the invention makes it possible to remove, at least partially, the inhibition of the transfection due to serum.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise"; and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Nucleic acid transfer agent comprising at least one cationic hydrophilic region capable of noncovalently combining with nucleic acids and at least one lipophilic region, these regions being connected to each other through a so-called "spacer" arm, and comprising, in addition, at least one disulphide bridge positioned such that its reduction causes partial degradation of the lipophilic region, or alternatively positioned such that its reduction causes separation of the said transfer agent when it is symmetrical.

2. Transfer agent according to claim 1, characterized in that the cationic hydrophilic region is a polyamine or a polyaminoguanidine.

3. Transfer agent according to claim 1, characterized in that the lipophilic region consists of at least one aliphatic fatty chain and of one or more aliphatic chains, of one or more steroid derivatives, of a natural or synthetic lipid and/or optionally of a combination of these.

4. Transfer agent according to claim 3, characterized in that the lipophilic region consists of two aliphatic fatty chains at least.

5. Transfer agent according to claim 3, characterized in that the lipophilic region consists of an aliphatic fatty chain and of a steroid derivative.

6. Transfer agent according to claim 3, characterized in that the aliphatic fatty chains are

linear or branched alkyl chains comprising 10 to 22 carbon atoms, optionally saturated and/or fluorinated.

7. Transfer agent according to claim 3, characterized in that the steroid derivative is chosen from cholesterol, cholic acid and cholesterylamine.

8. Transfer agent according to claim 1, characterized in that the so-called "spacer" arm is chosen from the amide, carbamate, ester and ether groups, and/or aromatic rings.

9. Transfer agent according to claim 1, characterized in that it comprises one or two disulphide bridges.

10. Transfer agent according to claim 1, characterized in that it comprises a disulphide bridge positioned such that its reduction causes the loss of an aliphatic fatty chain.

11. Transfer agent according to claim 1, characterized in that it comprises a disulphide bridge positioned such that its reduction causes the loss of a chain derived from a steroid present in the lipophilic region.

12. Transfer agent according to claim 1, characterized in that it is chosen from:

25 $\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys}[\text{S-S}-(\text{CH}_2)_4\text{CH}_3] -$

$\text{N}(\text{CH}_2)_{17}\text{CH}_3]_2$ (I);

$\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys}[\text{S-S}-(\text{CH}_2)_{17}\text{CH}_3] -$

$\text{NH}(\text{CH}_2)_{17}\text{CH}_3$ (II);

$\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys}[\text{S}-\text{S}-(\text{CH}_2)_{11}\text{CH}_3]-$
 $\text{NH}(\text{CH}_2)_{17}\text{CH}_3$ (III);

$\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys}[\text{S}-\text{S}-(\text{CH}_2)_{11}\text{CH}_3]-$
 $\text{N}[(\text{CH}_2)_{17}\text{CH}_3]_2$ (IV);

5 $\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCys}[\text{S}-\text{S}-\text{Cholesterol}]-$
 $\text{NH}(\text{CH}_2)_{17}\text{CH}_3$ (V);

$[\text{NH}_2(\text{CH}_2)_3\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_3\text{NHCH}_2\text{COCysNH}(\text{CH}_2)_{17}\text{CH}_3]_2$
 (VI).

13. Composition, characterized in that it
 10 comprises a transfer agent as defined in claims 1 to 12
 and at least one nucleic acid.

14. Composition according to claim 13,
 characterized in that the nucleic acid is a
 deoxyribonucleic acid or a ribonucleic acid.

15 15. Composition according to claim 13,
 characterized in that the nucleic acid is chemically
 modified.

16. Composition according to claim 13,
 characterized in that the nucleic acid is an anti-
 20 sense.

17. Composition according to claim 13,
 characterized in that the nucleic acid comprises a gene
 of therapeutic interest.

18. Composition according to claims 13 to
 25 17, characterized in that it comprises, in addition, an
 adjuvant consisting of one or more neutral lipids
 chosen from synthetic or natural lipids which are

zwitterionic or lack an ionic charge under physiological conditions.

19. Composition according to claim 18, characterized in that the neutral lipid(s) is(are)
5 cholesterol or lipids containing two fatty chains of the type comprising dioleoylphosphatidylethanolamine (DOPE), oleoylpalmitoylphosphatidylethanolamine (POPE), di-stearoyl, -palmitoyl, -cholesteryl, -myristoyl-phosphatidylethanolamines as well as their derivatives
10 which are N-methylated 1 to 3 times, phosphatidyl-glycerols, glycosyldiacylglycerols, cerebrosides (such as in particular galactocerebrosides), sphingolipids (such as in particular sphingomyelins), or asialo-gangliosides (such as in particular asialoGM1 and GM2).

15 20. Composition according to claim 13, characterized in that it comprises, in addition, an adjuvant which is or which comprises a compound derived as a whole or in part from a histone, a nucleolin and/or a protamine, or the said compound consists as a
20 whole or in part of peptide units (KTPKKAKKP) and/or (ATPAKKAA) repeated in a continuous manner or otherwise, it being possible for the number of units to vary between 2 and 10.

21. Composition according to claim 13,
25 characterized in that it combines, in addition, a targeting component with the transfer agent.

22. Composition according to claim 21, characterized in that the said targeting component is

chosen from antibodies directed against cell surface molecules, membrane receptor ligands such as insulin, transferrin, folic acid or any other growth factor, cytokines or vitamins, lectins, modified or otherwise, proteins with an RGD unit, peptides containing a tandem of RGD units, cyclic or otherwise, polylysine peptides as well as natural or synthetic ligand peptides.

23. Composition according to claim 13, characterized in that it incorporates, in addition, at least one nonionic surfactant of the type comprising poloxamers, polyoxyethylene alcohols, polyoxyethylene nonyl phenyl ether, or polyethylene glycols with a dendritic benzyl polyether head.

24. Use of a transfer agent as defined in any one of claims 1 to 12, for the transfer of nucleic acids into cells.

25. Method of transferring nucleic acids into cells, characterized in that it comprises the following steps:

(1) bringing the nucleic acid into contact with a transfer agent as defined in any one of claims 1 to 12 to form a nucleic acid/transfer agent complex, preceded, where appropriate, by the prior bringing of the transfer agent in to contact with one or more other agents known for the transfection of nucleic acids and/or with one or more adjuvants,

(2) bringing the cells into contact with the complex formed in (1).

26. Method of preparing a composition as defined in any one of claims 13 to 23, characterized in that a nucleic acid is brought into contact with a transfer agent as defined in any one of claims 1 to 12 to form a nucleic acid/transfer agent complex, preceded, where appropriate, by the prior bringing of the transfer agent into contact with one or more other agents known for the transfection of nucleic acids and/or with one or more adjuvants.

27. Method of treating diseases comprising the administration in *vivo*, *ex vivo* or *in vitro* of a composition as defined in any one of claims 13 to 23.

28. Use of a composition as defined in any one of claims 13 to 23 in the manufacture of a medicament to treat a disease.

29. Nucleic acid transfer agent according to claim 1 substantially



as hereinbefore described in any one of the Examples.

30. Composition according to claim 13 substantially as
hereinbefore described in any one of the Examples.

31. Use according to claim 24 substantially as hereinbefore
5 described in any one of the Examples.

32. Method according to claim 25 substantially as hereinbefore
described in any one of the Examples.

33. Method according to claim 26 substantially as hereinbefore
described in any one of the Examples.

10 34. Method according to claim 27 substantially as hereinbefore
described in any one of the Examples.

35. Use according to claim 28 substantially as hereinbefore
described in any one of the Examples.

15 Dated this 28th day of January 2003.

Aventis Pharma S.A.

By its Patent Attorneys

Davies Collison Cave




FIGURE 1


FIGURE 2

FIGURE 3

	nmol/ μ g of DNA	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	2.5 E+03	1.7 E+03
	4	3.7 E+03	2.9 E+03
	6	2.6 E+04	1.8 E+04
	8	3.1 E+04	2.2 E+04
Agent (VI)	2	1.1 E+03	7.7 E+02
	4	7.4 E+04	5.9 E+04
	6	1.1 E+05	9.6 E+04
	8	5.9 E+04	5.3 E+04

Tests on HepG2 cells

FIGURE 4

	nmol/ μ g of DNA	WITHOUT SERUM		WITH SERUM	
		RLU/5 μ l cellular extract/10 s	RLU/ μ g protein/10s	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	2.5 E+03	1.7 E+03	3.1 E+03	2.6 E+03
	4	3.7 E+03	2.9 E+03	5.3 E+01	4.1 E+01
	6	2.6 E+04	1.8 E+04	5.2 E+02	4.7 E+02
	8	3.1 E+04	2.2 E+04	5.3 E+02	4.0 E+02
Agent (I)	2	3.4 E+03	2.4 E+03	1.4 E+03	1.2 E+03
	4	4.7 E+03	3.7 E+03	2.6 E+03	2.3 E+03
	6	1.1 E+04	8.7 E+03	8.3 E+03	7.2 E+03
	8	4.4 E+04	3.3 E+04	1.5 E+04	1.2 E+04
Agent (IV)	2	5.9 E+03	4.4 E+03	2.5 E+03	2.2 E+03
	4	1.3 E+05	1.0 E+05	3.0 E+04	2.6 E+04
	6	2.2 E+05	1.7 E+05	4.4 E+04	4.1 E+04
	8	2.2 E+05	1.8 E+05	6.7 E+04	5.7 E+04

Tests on HepG2 cells

	nmol/ μ g of DNA	WITHOUT SERUM		WITH SERUM	
		RLU/5 μ l cellular extract/10 s	RLU/ μ g protein/10s	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	2.9 E+05	1.6 E+05	1.5 E+05	7.8 E+04
	4	2.2 E+06	1.7 E+06	6.8 E+03	3.5 E+03
	6	3.4 E+06	2.8 E+06	1.7 E+04	9.2 E+03
	8	4.3 E+06	3.5 E+06	2.8 E+04	1.5 E+04
Agent (I)	2	7.0 E+05	4.2 E+05	1.7 E+06	9.8 E+05
	4	5.2 E+06	3.3 E+06	7.9 E+06	4.7 E+06
	6	3.7 E+06	2.6 E+06	5.2 E+06	3.2 E+06
	8	3.3 E+06	2.3 E+06	4.5 E+06	2.7 E+06
Agent (IV)	2	5.2 E+05	3.4 E+05	4.3 E+05	2.8 E+05
	4	3.7 E+06	2.2 E+06	3.7 E+06	2.4 E+06
	6	7.1 E+06	4.7 E+06	5.1 E+06	4.1 E+06
	8	8.2 E+06	5.6 E+06	6.8 E+06	5.7 E+06

Tests on HeLa cells


FIGURE 5


FIGURE 6

FIGURE 7

	nmol/ μ g of DNA	WITHOUT SERUM		WITH SERUM	
		RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	2.5 E+03	1.7 E+03	3.1 E+03	2.6 E+03
	4	3.7 E+03	2.9 E+03	5.3 E+01	4.1 E+01
	6	2.6 E+04	1.8 E+04	5.2 E+02	4.7 E+02
	8	3.1 E+04	2.2 E+04	5.3 E+02	4.0 E+02
Agent (V)	2	4.3 E+01	3.4 E+01	1.5 E+01	1.8 E+01
	4	1.7 E+03	1.3 E+03	1.1 E+02	1.3 E+02
	6	1.7 E+04	1.6 E+04	2.2 E+03	3.0 E+03
	8	9.1 E+04	7.6 E+04	1.6 E+04	1.6 E+04

Tests on HepG2 cells


FIGURE 8

FIGURE 9

	nmol/ μ g of DNA	WITHOUT SERUM		WITH SERUM	
		RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	5.1 E+05	1.0 E+06	1.2 E+05	2.2 E+05
	4	1.2 E+05	2.3 E+05	1.0 E+04	1.9 E+04
	6	5.8 E+04	1.3 E+05	5.8 E+03	1.4 E+04
	8	2.1 E+04	3.6 E+04	3.3 E+03	7.3 E+03
Agent (V)	2	2.0 E+04	3.9 E+04	2.6 E+04	4.6 E+04
	4	1.3 E+05	2.3 E+05	5.4 E+04	9.0 E+04
	6	1.8 E+05	3.3 E+05	6.1 E+04	1.1 E+05
	8	3.2 E+05	6.0 E+05	7.1 E+04	1.3 E+05

Tests on HepG2 cells

	nmol/ μ g of DNA	WITHOUT SERUM		WITH SERUM	
		RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s	RLU/5 μ l cellular extract/10s	RLU/ μ g protein/10s
Reference cationic lipid REF	2	2.2 E+06	1.2 E+06	3.0 E+06	1.5 E+06
	4	5.9 E+06	3.4 E+06	5.1 E+03	2.0 E+03
	6	4.0 E+06	2.6 E+06	9.5 E+03	3.8 E+03
	8	1.2 E+06	6.8 E+05	4.2 E+03	1.6 E+03
Agent (V)	2	1.9 E+05	8.2 E+04	2.9 E+05	1.2 E+05
	4	7.9 E+05	3.3 E+05	1.0 E+06	4.1 E+05
	6	1.4 E+06	6.4 E+05	2.0 E+06	8.4 E+05
	8	3.0 E+06	1.5 E+06	5.0 E+06	2.1 E+06

Tests on HeLa cells